A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Bijoyesh Mookerjee, MD
Simcere Zaiming
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Anhui Provincial Hospital
Hefei, Anhui, China
- Fujian Cancer Hospital
Fuzhou, Fujian, China
- Henan Cancer Hospital
Zhengzhou, Henan, China
- Hunan Cancer Hospital
Changsha, Hunan, China
- Shandong Cancer Hospital
Jinan, Shandong, China
- the First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
- Nyu Langone
New York, New York, United States
- University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Mar 2023
- Primary completion
- 25 May 2024
- Completion
- 25 May 2024
- Last update posted
- 20 Dec 2024
- Registered enrollment
- 192
- Registry id
- NCT05781360
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.